TherapeuticsMD
TXMD
43 hedge funds and large institutions have $7.73M invested in TherapeuticsMD in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
100% more call options, than puts
Call options by funds: $32K | Put options by funds: $16K
10% more funds holding
Funds holding: 39 → 43 (+4)
2% more capital invested
Capital invested by funds: $7.61M → $7.73M (+$120K)
0.06% less ownership
Funds ownership: 31.98% → 31.92% (-0.06%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Clearline Capital
New York
|
+$160K |
| 2 |
CHAM
Clear Harbor Asset Management
Stamford,
Connecticut
|
+$59.8K |
| 3 |
PCG
Prosperity Consulting Group
Owings Mills,
Maryland
|
+$56.7K |
| 4 |
Renaissance Technologies
New York
|
+$31.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$15.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$305K |
| 2 |
GF
Gabelli Funds
Rye,
New York
|
-$39.4K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$6.71K |
| 4 |
A
AJOVista
Boston,
Massachusetts
|
-$4.84K |
| 5 |
BlackRock
New York
|
-$1.12K |
TXMD Hedge Fund Activity: Q1 2024 in Review
43 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2024, worth a combined $7.73M — up 1.6% from $7.61M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TXMD positions and 4 closed out — a net gain of 4 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Clearline Capital, adding an estimated $160K. The largest seller was Morgan Stanley, cutting an estimated $305K.
- 43 institutional investors held TherapeuticsMD (TXMD) as of Q1 2024, up from 39 in Q4 2023.
- Funds reported $7.73M of TherapeuticsMD stock for Q1 2024, up 1.6% quarter-over-quarter.
- 8 funds opened new TherapeuticsMD positions in Q1 2024 and 4 closed out, a net change of +4 holders.
- The largest TherapeuticsMD buyer in Q1 2024 was Clearline Capital, an estimated $160K added.
- The largest TherapeuticsMD seller in Q1 2024 was Morgan Stanley, an estimated $305K sold.
Based on aggregated 13F filings for Q1 2024.